Is the Salk principle still viable for the design of an effective HIV vaccine?
Lundgren
J D
JD
D016915:AIDS Vaccines; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D015164:Vaccines, Inactivated
D016915:AIDS Vaccines; D015164:Vaccines, Inactivated